Virtual Reality for External Cephalic Version

Overview

This will be a parallel design, nonblinded, randomized controlled superiority trial investigating the utility of a virtual reality (VR) experience to provide analgesia for external cephalic version (ECV).

Full Title of Study: “Virtual Reality Analgesia for External Cephalic Version”

Study Type

  • Study Type: Interventional
  • Study Design
    • Allocation: Randomized
    • Intervention Model: Parallel Assignment
    • Primary Purpose: Other
    • Masking: None (Open Label)
  • Study Primary Completion Date: August 2020

Detailed Description

Subjects will be: Pregnant women, age >18 years, with a singleton pregnancy at >36 weeks gestational age, healthy (American Society of Anesthesiologists physical status class II), with an otherwise uncomplicated pregnancy (i.e. no fetal abnormalities or significant maternal morbidity, scheduled for ECV at Columbia University Irving Medical Center (CUIMC) with a plan to receive no anesthesia for the procedure.

Patients will be randomly assigned to either the VR or No VR group. The intervention will be provided for the duration of the ECV procedure (typically 15 – 30 mins).

Interventions

  • Other: Virtual Reality Experience
    • Virtual reality visualization and experience of a 3-dimensional relaxing nature scene with the accompanying audio.

Arms, Groups and Cohorts

  • Experimental: Group VR
    • Virtual reality (VR) experience VR visualization of a 3-dimensional relaxing nature scene with the accompanying audio. The patient will be offered a selection of scenes from which to choose, played continuously on a Samsung Gear VRTM(San Jose, CA) headset and headphones. The goal is for the patient to use the intervention for the entire duration of the external cephalic version procedure (ECV), which typically lasts 15 – 30 minutes.The patient will also receive verbal reassurance and coaching as needed. The obstetrician will communicate as usual with the patient.
  • No Intervention: Group No VR
    • No intervention will be provided for the control group, who will receive usual management at CUMC, which involves provision of no analgesia or sedation for the procedure, which typically lasts 15 – 30 minutes. Verbal reassurance and coaching is routinely provided by caregivers, including encouraging deep breathing, particularly during painful manipulation of the abdomen, for the duration of the procedure. The obstetrician will communicate as usual with the patient – for example advising that he/she is about to begin the procedure and giving updates as to the degree of success.

Clinical Trial Outcome Measures

Primary Measures

  • Mean maximal numerical rating scale (NRS) score ( scale 0 – 10) for pain during the ECV procedure.
    • Time Frame: The maximal rated pain score will be determined within 5 minutes of the end of the ECV procedure.
    • Verbal rating of pain (scale 0 – 10) during ECV procedure, rated every 5 minutes

Secondary Measures

  • Success of ECV procedure
    • Time Frame: Within 5 minutes of the end of the ECV procedure
    • The successful manipulation of the fetus from the breech to cephalic position
  • Rating of the likelihood of choosing the analgesia technique received again
    • Time Frame: Within 2 hours of the end of the procedure
    • Verbal rating of likelihood to choose the analgesia technique received again (scale 1 – 5, where 1 = I would not utilize again, 5 = I would definitely utilize again)

Participating in This Clinical Trial

Inclusion Criteria

  • Pregnant women, age >18 years, with a singleton pregnancy at >36 weeks gestational age, healthy (American Society of Anesthesiologists physical status class II), with an otherwise uncomplicated pregnancy (i.e. no fetal abnormalities or significant maternal morbidity, scheduled for ECV at CUMC with a plan to receive no anesthesia for the procedure.

Exclusion Criteria

  • 1) severe claustrophobia or other psychological/psychiatric disorder which would prevent the use of a VR headset; 2) history of severe motion sickness, which may lead to nausea and vomiting or other discomfort with use of the a VR headset; 3) severe visual impairment, which may prevent appreciation of the visual aspects of the VR environment presented; 4) severe auditory impairment, which may prevent full appreciation of the sounds presented in the VR environment; 5) facial skin or scalp open lesions which could be irritated or risk infection to the patient or others if the VR headset is used; 6) other viral/bacterial/fungal infectious illnesses that could easily be spread by sharing of the device e.g. viral or bacterial conjunctivitis, meningitis, influenza, common cold, and other upper respiratory tract infections; 7) severe or uncontrolled seizure disorder, as the VR experience could invoke seizures 8) bulky hairstyles which would significantly impair correct fitting of the VR headset.

Gender Eligibility: Female

Pregnant women

Minimum Age: 18 Years

Maximum Age: 55 Years

Are Healthy Volunteers Accepted: Accepts Healthy Volunteers

Investigator Details

  • Lead Sponsor
    • Columbia University
  • Provider of Information About this Clinical Study
    • Sponsor
  • Overall Official(s)
    • Allison Lee, MD, Principal Investigator, Columbia University
  • Overall Contact(s)
    • Allison Lee, MD, 212 342 2028, al3196@cumc.columbia.edu

Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.

At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.